PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy.

Trial Profile

PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Cardiovascular disorders; Coronary disorders; Diabetic angiopathies; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PROactive; PROactive-10
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 19 May 2016 Results of a retrospective analysis on Cardiovascular Outcomes of EMPA-REG, PROactive, ORIGIN, SAVOR, EXAMINE, CANVAS, ELIXA, TECOS, LEADER studies, published in the Clinical Therapeutics
    • 01 Aug 2011 Results published in Diabetes, Obesity and Metabolism.
    • 15 Jul 2010 Results reported in a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top